Research and Markets has announced the addition of the "Optic Neuropathy - Pipeline Review, H2 2016" report to their offering.
Optic Neuropathy pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Optic Neuropathy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/mjw49n/optic_neuropathy
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005601/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.